Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial

作     者：Xiaoling Liao Shuo Feng Yicong Wang Yuesong Pan Weiqi Chen Hui Qu Xingquan Zhao Liping Liu Yongjun Wang Yilong Wang 

作者机构：Department of NeurologyBeijing Tiantan HospitalCapital Medical UniversityBeijingChina China National Clinical Research Center for Neurological DiseasesBeijing TiantanHospitalCapital Medical UniversityBeijingChina Chinese Institute for Brain ResearchBeijingChina National Center for Neurological DiseasesBeijingChina Advanced Innovation Center for Human Brain ProtectionCapital Medical UniversityBeijingChina Beijing Laboratory of Oral HealthCapital Medical UniversityBeijingChina 

出 版 物：《Stroke & Vascular Neurology》 (卒中与血管神经病学（英文）)

年 卷 期：2024年第9卷第1期

页      面：75-81,I0047-I0052页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the following grants:The National Natural Science Foundation of China(no.81825007) Beijing Outstanding Young Scientist Program(no.BJJWZYJH01201910025030) Youth Beijing Scholar Program(no.010) Beijing Talent Project-Class A:Innovation and Development(no.2018A12) 'National Ten-Thousand Talent Plan'-Leadership of Scientific and Technological Innovation National Key R&D Program of China(no.2017YFC1307900,2017YFC1307905) Grand Pharmaceutical Group Co has been providing tirofiban and its placebo free of cost and without any limitations 

主　　题：Aspirin regimen centre 

摘      要：Background Perforating artery territorial infarction(PAI)caused by branch atheromatous disease(BAD)is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment ***,an adjunctive antiplatelet agent,has shown great potential to treat acute ischaemic ***,whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains *** To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration(END)in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin *** Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction(STRATEGY)trial is an ongoing multicentre,randomised,placebo-controlled trial in *** patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to *** primary endpoint is a new stroke or END within 90 *** primary safety endpoint is severe or moderate bleeding within 90 *** The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with *** registration number NCT05310968.